Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 145

1.

Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen.

Lash TL, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL, Silliman RA, Hamilton-Dutoit S, Garne JP, Ewertz M, Sørensen HT, Pedersen L.

Acta Oncol. 2010 Apr;49(3):305-12. doi: 10.3109/02841860903575273.

2.

Tamoxifen's protection against breast cancer recurrence is not reduced by concurrent use of the SSRI citalopram.

Lash TL, Pedersen L, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL, Silliman RA, Hamilton-Dutoit S, Garne JP, Ewertz M, Sørensen HT.

Br J Cancer. 2008 Aug 19;99(4):616-21. doi: 10.1038/sj.bjc.6604533. Epub 2008 Jul 29.

3.

CYP2D6 inhibition and breast cancer recurrence in a population-based study in Denmark.

Lash TL, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL, Silliman RA, Garne JP, Sørensen HT, Hellberg Y, Christensen M, Pedersen L, Hamilton-Dutoit S.

J Natl Cancer Inst. 2011 Mar 16;103(6):489-500. doi: 10.1093/jnci/djr010. Epub 2011 Feb 15.

4.

Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study.

Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC, Paszat LF.

BMJ. 2010 Feb 8;340:c693. doi: 10.1136/bmj.c693.

5.

No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications.

Ahern TP, Pedersen L, Cronin-Fenton DP, Sørensen HT, Lash TL.

Cancer Epidemiol Biomarkers Prev. 2009 Sep;18(9):2562-4. doi: 10.1158/1055-9965.EPI-09-0516. Epub 2009 Aug 18.

6.

Tamoxifen and Antidepressant Drug Interaction in a Cohort of 16,887 Breast Cancer Survivors.

Haque R, Shi J, Schottinger JE, Ahmed SA, Cheetham TC, Chung J, Avila C, Kleinman K, Habel LA, Fletcher SW, Kwan ML.

J Natl Cancer Inst. 2015 Dec 1;108(3). doi: 10.1093/jnci/djv337. Print 2016 Mar.

7.

Effect of selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality: a population-based study.

Valachis A, Garmo H, Weinman J, Fredriksson I, Ahlgren J, Sund M, Holmberg L.

Breast Cancer Res Treat. 2016 Sep;159(2):293-303. doi: 10.1007/s10549-016-3928-3. Epub 2016 Aug 5.

8.

CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.

Jin Y, Desta Z, Stearns V, Ward B, Ho H, Lee KH, Skaar T, Storniolo AM, Li L, Araba A, Blanchard R, Nguyen A, Ullmer L, Hayden J, Lemler S, Weinshilboum RM, Rae JM, Hayes DF, Flockhart DA.

J Natl Cancer Inst. 2005 Jan 5;97(1):30-9.

PMID:
15632378
9.

Selective serotonin reuptake inhibitors and adjuvant tamoxifen therapy: risk of breast cancer recurrence and mortality.

Cronin-Fenton D, Lash TL, Sørensen HT.

Future Oncol. 2010 Jun;6(6):877-80. doi: 10.2217/fon.10.65. No abstract available.

10.

Do selective serotonin receptor inhibitor antidepressants reduce tamoxifen's effectiveness and increase the risk of death from breast cancer?

Pritchard KI.

Breast Cancer Res. 2010 Dec 20;12 Suppl 4:S18. doi: 10.1186/bcr2747. No abstract available.

11.

Physicians' assessments of adjuvant tamoxifen's effectiveness in older patients with primary breast cancer.

Lash TL, Gurwitz JH, Silliman RA.

J Am Geriatr Soc. 2005 Nov;53(11):1889-96.

PMID:
16274369
12.

Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer.

Dezentjé VO, van Blijderveen NJ, Gelderblom H, Putter H, van Herk-Sukel MP, Casparie MK, Egberts AC, Nortier JW, Guchelaar HJ.

J Clin Oncol. 2010 May 10;28(14):2423-9. doi: 10.1200/JCO.2009.25.0894. Epub 2010 Apr 12.

PMID:
20385997
13.

Concurrent use of tamoxifen with CYP2D6 inhibitors and the risk of breast cancer recurrence.

Azoulay L, Dell'Aniello S, Huiart L, du Fort GG, Suissa S.

Breast Cancer Res Treat. 2011 Apr;126(3):695-703. doi: 10.1007/s10549-010-1162-y. Epub 2010 Sep 17.

PMID:
20848186
14.

Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis.

Punglia RS, Burstein HJ, Winer EP, Weeks JC.

J Natl Cancer Inst. 2008 May 7;100(9):642-8. doi: 10.1093/jnci/djn100. Epub 2008 Apr 29.

15.

Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004-2010.

Dusetzina SB, Alexander GC, Freedman RA, Huskamp HA, Keating NL.

Breast Cancer Res Treat. 2013 Jan;137(1):285-96. doi: 10.1007/s10549-012-2330-z. Epub 2012 Nov 13.

16.

Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.

Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, Hayes DF, Desta Z, Flockhart DA.

J Natl Cancer Inst. 2003 Dec 3;95(23):1758-64.

PMID:
14652237
17.

Risk of mortality with concomitant use of tamoxifen and selective serotonin reuptake inhibitors: multi-database cohort study.

Donneyong MM, Bykov K, Bosco-Levy P, Dong YH, Levin R, Gagne JJ.

BMJ. 2016 Sep 30;354:i5014. doi: 10.1136/bmj.i5014.

18.

Venlafaxine extended release versus citalopram in patients with depression unresponsive to a selective serotonin reuptake inhibitor.

Lenox-Smith AJ, Jiang Q.

Int Clin Psychopharmacol. 2008 May;23(3):113-9. doi: 10.1097/YIC.0b013e3282f424c2.

PMID:
18408525
19.

Clinical significance of CYP2D6 polymorphisms and tamoxifen in women with breast cancer.

Gaston C, Kolesar J.

Clin Adv Hematol Oncol. 2008 Nov;6(11):825-33.

PMID:
19194367
20.

Pak1, adjuvant tamoxifen therapy, and breast cancer recurrence risk in a Danish population-based study.

Ahern TP, Cronin-Fenton DP, Lash TL, Sørensen HT, Ording AG, Hamilton-Dutoit SJ, Hellberg Y.

Acta Oncol. 2016 Jun;55(6):734-41. doi: 10.3109/0284186X.2016.1150606. Epub 2016 Apr 8.

Supplemental Content

Support Center